| Name | Number of Reports | Reference(s) | Data Source | |
|---|---|---|---|---|
| 1 | Rivaroxaban | FAERS: 38 | US FAERS | |
| 2 | Dabigatran | FAERS: 4 | US FAERS | |
| 3 | rofecoxib | FAERS: 4 | US FAERS | |
| 4 | Rivastigmine | FAERS: 2 | US FAERS | |
| 5 | Cilostazol | FAERS: 1 | US FAERS | |
| 6 | Clopidogrel | FAERS: 1 | US FAERS | |
| 7 | Dasatinib | FAERS: 1 | US FAERS | |
| 8 | Deferasirox | FAERS: 1 | US FAERS | |
| 9 | Octreotide | FAERS: 1 | US FAERS | |
| 10 | Prasugrel Hydrochloride | FAERS: 1 | US FAERS | |
| 11 | Ranolazine | FAERS: 1 | US FAERS | |
| 12 | Sitagliptin Phosphate | FAERS: 1 | US FAERS | |
| 13 | Tirofiban | FAERS: 1 | US FAERS | |
| 14 | Warfarin | FAERS: 1 | US FAERS | |
| 15 | Zoledronic Acid | FAERS: 1 | US FAERS | |
| 16 | ambrisentan | FAERS: 1 | US FAERS | |
| 17 | fenoterol, ipratropium drug combination | OFFSIDES |
Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120266
Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.